Antimalarial combinations

Lancet

Volumn 364, Issue 9430, 2004, Pages 285-294

  Kremsner, Prof Peter Gottfried ^a,b   Krishna, Prof Sanjeev ^a,c  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; FANSIDAR; MEFLOQUINE; QUININE; TETRACYCLINE;

ALLERGIC REACTION; ANEMIA; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; GENOME; HEMOLYSIS; HUMAN; MALARIA; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PARASITE; PARASITE SURVIVAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STILLBIRTH; TINNITUS;

EID: 3242692444     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16680-4     Document Type: Review

References (113)

1. Honigsbaum M. The fever trail. 2001;MacMillan, London
2. Laveran CA. Un noveau parasite trouvé dans le sang des malades atteints de fièvre palustre. Orgine parasitaire des accidents de l'impaludisme. Bull Mém Soc Méd Hôp Paris. 17:1880;158-164
3. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clinical Pharmacokinetics. 30:1996;263-299
4. D'Alessandro U, Buttiens H. History and importance of antimalarial drug resistance. Trop Med Int Health. 6:2001;845-848
5. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy. Trans R Soc Trop Med Hyg. 88:1994;324-327
6. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44: 547-552.
7. Collignon P. Chloroquine resistance in Plasmodium vivax. J Infect Dis. 164:1991;222-223
8. Marler-Than, Myat-Phone-Kyaw, Aye-Yu-Soe, Khaing-Khaing-Gyi, Ma-Sabai, Myint-Oo. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg 1995; 89: 307-08.
9. Price RN, Nosten F. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug resist updat. 4:2001;187-196
10. Kremsner PG, Radloff P, Metzger W, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 39:1995;1603-1605
11. White N. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol. 92:1998;449-458
12. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419:2002;498-511
13. Basham D, Brown D, Chillingworth T, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 393:1998;537-544
14. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciaprum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA. 91:1994;1143-1147
15. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. PgH1 modulates sensitivity and resistance ot multiple antimalarials in Plasmodium falciparum. Nature. 403:2000;906-909
16. Warhurst DC. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 344:2001;299-302
17. Vaidya AB. Atovaquone-proguanil combination. Rosenthal PJ. Antimalarial chemotherapy. 1st edn :2001;396 Humana Press, Totowa
18. Rathod PK, McErlean T, Lee P-C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 94:1997;9389-9393
19. Nakazawa S, Maoka T, Uemura H, Ito Y, Kanbara H. Malaria parasites giving rise to recrudescence in vitro. Antimicrob Agents Chemother. 46:2002;958-965
20. ter Kuile FO, White NJ, Holloway PA, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of antimalarials used for the treatment of severe malaria. Exp Parasitol. 76:1993;85-95
21. Giao PT, Binh TQ, Kager PA, et al. Artemisinin for treatment of uncomplicated falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg. 65:2001;690-695
22. White NJ, Krishna S. Treatment of malaria: some considerations and limitations of current methods of assessment. Trans R Soc Trop Med Hyg. 83:1989;767-777
23. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 41:1997;1413-1422
24. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood. 90:1997;2037-2040
25. Watkins WM, Woodrow C, Marsh K. Falciparum malaria: differential effects of antimalarial drugs in ex-vivo parasite viability during the critical early phase of therapy. Am J Trop Med Hyg. 49:1993;106-112
26. Udomsangpetch R, Pipitaporn B, Krishna S, et al. Antimalarial drugs reduce cytoadherence and rosetting of Plasmodium falciparum. J Infect Dis. 173:1996;691-698
27. van Hensbroek MB, Onyiorah E, Jaffer S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med. 335:1996;69-75
28. Artemether Quinine Meta-analysis Study Group. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans R Soc Trop Med Hyg. 95:2001;637-650
29. Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculier kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother. 39:1995;1530-1537
30. Divo AA, Geary TG, Jensen JB. Oxygen and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Antimicrob Agents Chemother. 27:1985;21-27
31. Brandts CH, Ndjave M, Graninger W, Kremsner PG. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet. 350:1997;704-709
32. Lell B, Sovric M, Schmid D, et al. Effect of antipyretic drugs in malaria. Clin Infect Dis. 32:2001;838-841
33. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 18:2002;458-464
34. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinetics. 40:2001;343-373
35. Kun JFK, Mordmüller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promotor region of inducible nitric oxide synthase gene and protection against malaria. Lancet. 351:1998;265-266
36. Kremsner PG, Winkler S, Brandts CH, Graninger W, Bienzle U. Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg. 49:1993;650-654
37. Peters W. The chemotherapy of rodent malaria, LVII: drug combinations to impede the selection of drug resistance, part 1: which model is appropriate. Ann Trop Med Parasitol. 93:1999;569-587
38. Peters W. Antimalarial drug resistance. Br Med Bull. 38:1982;187-192
39. Peters W. Chemotherapy and drug resistance in malaria. 2nd edn :1987;Academic Press, London
40. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 356:2000;297-302
41. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis. 188:2003;1231-1238
42. Targett G, Drakeley C, Jawara M, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 183:2001;1254-1259
43. Fleck SL, Pudney M, Sinden RE. The effect of atovaquone (566C80) on the maturation and viability of Plasmodium falciparum gametocytes in vitro. Trans R Soc Trop Med Hyg. 90:1996;309-312
44. Amies CR. The effect of quinine on the production of gametocytes in subtertian malaria. Bull Inst Med Research, Federated Malay States. 2:1930;1-16
45. von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet. 355:2000;352-357
46. von Seidlein L, Walraven G, Milligan PJM, et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo controlled trial in The Gambia. Trans R Soc Trop Med Hyg. 97:2003;129-256
47. Clyde DF, Shute GT. Resistance of Plasmodium falciparum in Tanganyika to pyrimethamine administered at weekly intervals. Trans R Soc Trop Med Hyg. 51:1957;505-513
48. Plowe CV. Folate antagonists and mechanisms of resistance. Rosenthal PJ. Antimalarial chemotherapy. 2001;173-190 Humana Press, Totowa
49. Yuvaniyama J, Chitnumsub P, Kamchongwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 10:2003;357-365
50. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Trop. 56:1994;143-156
51. Mordmuller B, Graninger W, Kremsner PG. Malaria therapy in the era of chloroquine resistance. Wien Klin Wochenschr. 110:1998;321-325
52. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet. 341:1993;1299-1303
53. Schurmann D, Bergmann F, Albrecht H, et al. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumosystis carinii pneumonia relapse and toxoplasma encephalitis in patients with AIDS. J Infect Dis. 42:2001;8-15
54. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 357:2001;1471-1477
55. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine- pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 353:1999;632-636
56. Slater AF. Chloroquine: mechanisms of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. 57:1993;203-235
57. McIntosh HM, Greenwood BM. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria: a systematic review. Ann Trop Med Parasitol. 92:1998;265-270
58. Bojang KA, Schneider G, Forck S, et al. A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg. 92:1998;73-76
59. Schwobel B, Jordan S, Vanisaveth V, et al. Therapeutic efficacy of chloroquine plus sulphadoxine/pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. Trop Med Int Health. 8:2003;19-24
60. Olliaro P, Nevill C, LeBras J, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet. 348:1996;1196-1201
61. Olliaro P, Mussano P. Amodiaquine for treating malaria (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
62. Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1:1986;411-414
63. Luzzi GA, Peto TEA. Adverse effects of antimalarials: an update. Drug Safety. 8:1993;295-311
64. Schellenberg D, Kahigwa E, Drakely C, et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 67:2002;17-23
65. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 360:2002;2031-2038
66. Gasasira AF, Dorsey G, Nzarubara B, et al. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg. 68:2003;127-132
67. Kremsner PG, Krishna S. Antimalarial cocktails: tropical flavours of the month. Lancet. 360:2002;1998-1999
68. Kremsner PG, Zotter GM, Feldmeier H, Graninger W, Rocha RM, Wiedermann G. A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil. J Infect Dis. 158:1988;1368-1371
69. Rahman MR, Paul DC, Rashid M, et al. A randomized controlled trial on the efficacy of alternative treatment regimens for uncomplicated falciparum malaria in a multidrug-resistant falciparum area of Bangladesh: narrowing the options for the National Malaria Control Programme? Trans R Soc Trop Med Hyg. 95:2001;661-667
70. Athan E, Durrheim DN, Barnes K, Mngomezulu NM, Mabuza A, Govere J. Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa. S Afr Med J. 91:2001;592-594
71. Lell B, Lehman LG, Schmidt-Ott JR, Sturchler D, Handschin J, Kremsner PG. Malaria chemotherapy trial at a minimal effective dose of mefloquine/ sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/ pyrimethamine or mefloquine alone. Am J Trop Med Hyg. 58:1998;619-624
72. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 54:1996;62-66
73. Canfield CJ, Pudney M, Gutteridge W. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol. 80:1995;373-381
74. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther. 61:1997;518-530
75. Edstein MD, Looareesuwan S, Viravan C, Kyle DE. Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. Southeast Asian J Trop Med Public Health. 27:1996;216-220
76. Radloff PD, Phillipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Pladmosium falciparum malaria. Lancet. 347:1996;1511-1514
77. Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet. 351:1998;709-713
78. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis. 3:2003;162-168
79. Alloueche A, Bailey W, Barton S, et al. Comparision of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 363:2004;1843-1848
80. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 22:2001;298-305
81. Wilairatana P, Kyle DE, Looareesuwan S, et al. Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann Trop Med Parasitol. 91:1997;125-132
82. Fungladda W, Honrado ER, Thimasarn K, et al. Compliance with artesunate and quinine+tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 1998; 76 (suppl): 57-62.
83. Honrado ER, Fungladda W, Kamoiratanaku P, et al. Cost-effectiveness analysis of artesunate and quinine+tetracyline for the treatment of uncomplicated falciparum malaria in Chantaburi, Thailand. Bull World Health Organ. 77:1999;235-243
84. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG. High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. Antimicrob Agents Chemother. 39:1995;245-246
85. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 169:1994;467-470
86. McGready R, Cho T, Samuel, et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2001; 95: 651-656.
87. Parola P, Ranque S, Badiaga S, et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother. 45:2001;932-935
88. Lell B, Kremsner PG. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother. 46:2002;2315-2320
89. Hien TT, White NJ. Qinghaosu. Lancet. 341:1993;603-608
90. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 424:2003;957-961
91. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem. 274:1999;19383-19388
92. Jefford CW. Why artemisinin and certain synthetic peroxides are potent antimalarials: implications for the mode of action. Curr Med Chem. 8:2001;1803-1826
93. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol. 32:2002;1655-1660
94. Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian J Trop Med Public Health. 22:1991;534-538
95. Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 359:2002;1365-1372
96. International Artemisinin Study Group. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 363:2004;9-17
97. White N, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinetics. 37:1999;105-125
98. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 94:2000;419-424
99. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 98:2004;261-267
100. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White N. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 44:2000;697-704
101. von Seidlein L, Jaffar S, Pinder M, et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis. 176:1997;1113-1116
102. von Seidlein L, Bojang K, Jones P, et al. A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated in African children. Am J Trop Med Hyg. 58:1998;638-644
103. van Vugt M, Brockman A, Gemperli B, et al. Randomized comparison of artemether-benflumetol and artesunate-meflquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 42:1998;135-139
104. van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 94:2000;545-548
105. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 64:2001;247-256
106. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis. 170:1994;971-977
107. Marquino W, Huilca M, Calampa C, et al. Efficacy of mefloquine and mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am J Trop Med Hyg. 68:2003;608-612
108. Massougbodji A, Kone M, Kinde-Gazard D, Same-Ekobo A, Cambon N, Mueller EA. A randomized, double-blind study on the efficacy of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. Trans R Soc Trop Med Hyg. 96:2002;655-659
109. Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 35:2002;1469-1476
110. Hien TT, Dolecek C, Mai PP, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet. 363:2004;18-22
111. Missinou MA, Borrmann S, Schindler A, et al. Fosmidomycin for malaria. Lancet. 360:2002;1941-1942
112. Lell B, Ruangweerayut R, Wiesner J, et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother. 47:2003;735-738
113. Borrmann S, Adegnika AA, Matsiegui PB, et al. Fosmidomycin-clindamycin in Plasmodium falciparum infections in African children. J Infect Dis 2004; 189: 901-08 (published online, Feb 16, 2004).